Verrica Pharmaceuticals (VRCA) The Citizens JMP Life Sciences Conference 2025 summary

Commercial strategy and execution

• Implemented a new commercial strategy for YCANTH, targeting both pediatricians and dermatologists for molluscum contagiosum treatment.

• Reduced company costs by over half and achieved sequential quarterly growth of 12% in Q4 and 16% in Q1 for dispensed applicators.

• Expanded distribution through specialty pharmacy and buy-and-bill models, increasing access and insurance coverage.

• Adjusted copay program to $25 max out-of-pocket, improving patient access.

• Enhanced brand awareness and operational efficiency with a new entrepreneurial management team.

Financial position and management

• Ended last year with $46 million in cash and equivalents, plus a $50 million debt facility.

• Raised $42 million in November, providing a cash runway into next year, contingent on debt covenants.

• New management team focused on execution and operational efficiency.

Product and clinical data

• YCANTH is the only FDA-approved topical treatment for molluscum, with a robust safety and efficacy profile.

• Phase III trials showed nearly 50% complete clearance in four weeks, compared to 15% for placebo.

• Most adverse events were mild to moderate local skin reactions; no serious adverse events reported.

• Product is shelf-stable for two years and uses a single-use applicator to prevent cross-contamination.